



UNIVERSITÀ
DEGLI STUDI
DI UDINE

Università degli studi di Udine

Management of KPC-Producing *Klebsiella pneumoniae* Infections

Original

Availability:

This version is available <http://hdl.handle.net/11390/1117739> since 2017-09-17T08:36:12Z

Publisher:

Published

DOI:10.1016/j.cmi.2017.08.030

Terms of use:

The institutional repository of the University of Udine (<http://air.uniud.it>) is provided by ARIC services. The aim is to enable open access to all the world.


Publisher copyright

(Article begins on next page)

Accepted Manuscript

Management of KPC-Producing *Klebsiella pneumoniae* Infections

M. Bassetti, D.R. Giacobbe, H. Giamarellou, C. Viscoli, G.L. Daikos, G. Dimopoulos, F.G. De Rosa, E.J. Giamarellos-Bourboulis, G.M. Rossolini, E. Righi, I. Karaikos, M. Tumbarello, D.P. Nicolau, P.L. Viale, G. Poulakou



PII: S1198-743X(17)30499-8

DOI: [10.1016/j.cmi.2017.08.030](https://doi.org/10.1016/j.cmi.2017.08.030)

Reference: CMI 1063

To appear in: *Clinical Microbiology and Infection*

Received Date: 9 May 2017

Revised Date: 17 August 2017

Accepted Date: 23 August 2017

Please cite this article as: Bassetti M, Giacobbe DR, Giamarellou H, Viscoli C, Daikos GL, Dimopoulos G, De Rosa FG, Giamarellos-Bourboulis EJ, Rossolini GM, Righi E, Karaikos I, Tumbarello M, Nicolau DP, Viale PL, Poulakou G, Management of KPC-Producing *Klebsiella pneumoniae* Infections, *Clinical Microbiology and Infection* (2017), doi: 10.1016/j.cmi.2017.08.030.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Management of KPC-Producing *Klebsiella pneumoniae* Infections

M. Bassetti^{1*}, D.R. Giacobbe², H. Giamarellou³, C.Viscoli², G.L. Daikos⁴, G.

Dimopoulos⁵, F.G. De Rosa⁶, E.J. Giamarellos-Bourboulis⁷, G.M. Rossolini^{8,9}, E. Righi

¹, I. Karaikos³, M. Tumbarello¹⁰, D.P. Nicolau^{11,12}, P.L. Viale¹³, G. Poulakou¹⁴

¹ Infectious Diseases Clinic, Department of Medicine University of Udine and Azienda Sanitaria Universitaria Integrata, Presidio Ospedaliero Universitario Santa Maria della Misericordia, Udine, Italy

² Infectious Diseases Unit, Ospedale Policlinico San Martino – IRCCS per l'Oncologia, University of Genoa (DISSAL), Genoa, Italy

³ ⁶th Department of Internal Medicine, Hygeia General Hospital, 4, Erythrou Stavrou Str & Kifisias, Marousi, Athens, Greece

⁴ ¹st Department of Propaedeutic Medicine, Laikon Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece

⁵ Department of Critical Care, University Hospital Attikon, Medical School, University of Athens, Athens, Greece

⁶ Department of Medical Science, University of Turin, Infectious Diseases Amedeo di Savoia Hospital, Turin, Italy

⁷ ⁴th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece

⁸ Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

⁹ Clinical Microbiology and Virology Unit, Florence Careggi University Hospital, Florence, Italy.

¹⁰ Institute of Infectious Diseases Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli, Roma Italy

¹¹ Center for Anti-infective Research and Development, Hartford Hospital, Hartford, CT, USA

¹² Div. of Infectious Diseases, Hartford Hospital, Hartford, CT, USA

25 ¹³ Clinic of Infectious Diseases, Department of Internal Medicine, Geriatrics and Nephrologic Diseases, S. Orsola-
26 Malpighi Hospital, University of Bologna, Bologna, Italy.

27 ¹⁴ 4th Department of Internal Medicine, Athens University School of Medicine, Attikon University General
28 Hospital, Athens, Greece

29

30 **Running title:** Management of KPC-KP infections

31

32 * Corresponding author:

33 Prof. Matteo Bassetti

34 Infectious Diseases Clinic, Department of Medicine University of Udine and Azienda

35 Sanitaria Universitaria Integrata

36 Presidio Ospedaliero Universitario Santa Maria della Misericordia, Udine, Italy

37 Piazzale Misericordia 15 - 33100 Udine (Italy)

38 Tel +39 0432 559353

39 Fax +39 0432 559360

40 Electronic address: mattba@tin.it, matteo.bassetti@uniud.it

41

42 **Abstract**

43

44 **Background:** *Klebsiella pneumoniae* carbapenemase (KPC)-producing *K. pneumoniae*
45 (KPC-KP) has become one of the most important contemporary pathogens,
46 especially in endemic areas.

47 **Aims:** our aim was to provide practical suggestion for physicians dealing with the
48 management of KPC-KP infections in critically ill patients, based on expert opinions.

49 **Sources:** PubMed search for relevant publications related to the management of
50 KPC-KP infections.

51 **Contents:** a panel of experts developed a list of 12 questions to be addressed. In
52 view of the current lack of high-level evidence, they were asked to provide answers
53 based on their knowledge and experience in the field. The panel identified several
54 key aspects to be addressed when dealing with KPC-KP in critically-ill patients
55 (preventing colonization in the patient, preventing infection in the colonized patient
56 and colonization of his/her contacts, reducing mortality in the infected patient by
57 rapidly diagnosing the causative agent and promptly adopting the best therapeutic
58 strategy) and provided related suggestions on the basis the available observational
59 literature and the experience of panel members.

60 **Implications:** Diagnostic technologies could speed-up the diagnosis of KPC-KP
61 infections. Combination treatment should be preferred to monotherapy in the case
62 of severe infections. For non-critically-ill patients without severe infections, results
63 from randomized clinical trials are needed for ultimately weighing benefits and costs
64 of using combinations rather than monotherapy. Multifaceted infection-control
65 interventions are needed to decrease the rates of colonization and cross-
66 transmission of KPC-KP.

67

68 **Introduction**

69 Management of infections caused by multidrug-resistant bacteria impacts
70 considerably on health costs and becomes major modifier of health expenses in the
71 ongoing antibiotic resistance crisis.¹ *Klebsiella pneumoniae* carbapenemase (KPC)-
72 producing *K. pneumoniae* (KPC-KP), has become one of the most important
73 contemporary pathogens, especially in endemic areas.²⁻⁴ KPC-KP optimal treatment,
74 however, is not known and there are currently no published recommendations for
75 the management of infections by KPC-KP. Given the observational nature of the
76 majority of studies on this topic, many of the recommendations listed in this
77 manuscript arise from acquired experience of the invited panel members, and
78 therefore represent expert opinion.

79 **Purpose and methods**

80 The purpose of this paper was to answer practical questions for physicians dealing
81 with the treatment of KPC-KP infections in critically ill patients, in view of the
82 fragmentation in the observational literature on this topic and the lack of
83 randomized clinical trials.⁵ A panel of 11 experts developed a list of questions to be
84 addressed in the paper; 12 questions were formulated after rounds of discussion
85 between chairs (M. Bassetti, G. Poulakou, C. Viscoli, and H. Giamarellou) and panel
86 members. In view of the lack of high-level evidence, panel members were asked to
87 provide narrative answers on the basis of their knowledge and experience in the
88 field. Finally, provided answers were reviewed and discussed by the panel, until a

consensus was reached. The final summary of selected questions and related answers is presented in table 1.

Background information for provided answers

1. How can the laboratory speed-up KPC-KP identification and susceptibility testing?

Rapid methods for identification of strains producing KPC and other carbapenemases are important to ensure appropriate and early initiation of specific therapy, as well as the prompt implementation of the most appropriate infection control measures.⁶

This is particularly relevant with KPC-KP or other types of carbapenemase-producing Enterobacteriaceae (CPE) infections, since commonly used regimens for empiric antimicrobial chemotherapy do not normally cover for MDR pathogens, except under specific circumstances (e.g., febrile neutropenia in a patient who is known to be colonized by KPC-KP).⁷

Several new diagnostic technologies have recently become available to allow increased rapidity of microbiological diagnosis, including Matrix Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS), rapid immunochromatography, rapid enzymatic assays (such as the Carba NP test), single-cell automated time-lapse microscopy and molecular biology-based assays.⁸⁻¹⁰ These new technologies may be very useful to reduce the time for pathogen identification (ID) and antibiotic susceptibility test (AST) .

MALDI-TOF MS has proven very successful in rapid bacterial identification from isolated colonies or monomicrobial blood cultures. MALDI-TOF MS can also be

used for rapid detection of some resistance determinants, such as beta-lactamases.¹¹

A mass spectrometric beta-lactamase (MSBL) assay represents a functional assay based on the direct monitoring of the enzymatic activity of the beta-lactamase and can be performed with bacterial cultures or directly from freshly tagged positive blood cultures, with results available after 1 - 4 hour incubation period.¹¹ Both imipenem and meropenem can be used in these tests, with meropenem being somewhat more efficient.¹²

This method, however, cannot identify the type of beta-lactamase. Recently, the identification of a 11,109-Da MS peak corresponding to a gene product of the *bla_{KPC}* pKpQIL plasmid was found to be useful in rapid tracking KPC-producing strains.¹³

Diagnostic platforms capable of rapid detection of *bla_{KPC}* genes based on molecular biology techniques are currently available to target carbapenemase genes (e. g. Xpert® Carba-R or Check-Direct® CPE) in bacterial cultures or rectal swabs.¹⁴ Others can identify *bla_{KPC}* and other clinically relevant resistance genes directly from positive blood culture (e.g., FilmArray® BC-ID or Verigene®). Remarkably, in this case, the results are provided in about one hour compared to conventional microbiological methods that may take from 12 up to 72 hours.¹⁵ More recently, a polymerase chain reaction/electrospray ionization-mass spectrometry platform (IRIDICA®) that detects more than 800 BSI-relevant pathogens and also *bla_{KPC}* genes in approximately 6 hours was developed.¹⁶

It should be noted that detection of resistance mechanisms by molecular biology is useful to rapidly predict potential resistance to some agents, but does not provide comprehensive information about the resistance phenotype of the infecting strain,

and conventional AST remains the cornerstone for selection of definitive treatment regimens and evaluation of adequate / inadequate antimicrobial chemotherapy.¹⁷ However, the rapid detection of some resistance mechanism, and of KPC genes in particular (the presence of which means most of the time resistance to carbapenems and even multiresistance), can be very useful for an earlier revision of empiric regimens, which usually do not cover CPE.

Availability of rapid diagnostic methods is associated with decreased length of stay, lower mortality and reduced costs in the long-term, provided that their implementation is feasible.⁶ Indeed, in some cases these techniques may represent an unaffordable expensive add-on to the routine diagnostic laboratory workflow, in terms of reagents and manpower cost, requiring a 24/7 schedule of sample processing. Furthermore, the information provided for AST is different from conventional minimum inhibitory concentration (MIC) values and must be suitably conveyed to the clinician to avoid confusion. Overall, microbiology laboratories should have protocols for immediate notification of clinical teams whenever a CPE infection is identified

2. What is currently the best treatment for KPC-KP infections?

A necessary premise is that only low-level evidence with a high risk of bias is available from observational studies regarding the optimal treatment for KPC-KP infections, thus not allowing for definite conclusions.^{5,18,19} In this light, the following statements are to be weighed cautiously, pending results of randomized clinical trials

(NCT01597973 and the AIDA study²⁰ are ongoing or are have been recently completed, respectively).

Since monotherapy appeared to be associated with higher mortality rates compared to combination therapy for the targeted treatment of KPC-KP in observational studies, the use of combined regimens should be preferred in patients with severe KPC-KP infections.^{19,21-25} Indeed, the positive impact of combination therapy on survival might be true only in patients with severe infections compared to less severe BSI and in non-bacteraemic intra-abdominal or UTIs, a fact which is also in line with the favourable survival effect of combinations recently observed only in patients with a high INCREMENT-CPE mortality score.^{23,25} In patients at lower risk of mortality, no clear survival benefit of combinations over monotherapy has been demonstrated. In these patients, a conservative combination approach might be used at the beginning, with the option of de-escalating to a simpler regimen in correlation with patient's clinical conditions. However, the risk of inducing further resistance by the use of last-resort antibiotics is a non-negligible risk, and results from randomized clinical trials are needed for ultimately weighing benefits and cost of using combinations in patients with non-severe KPC-Kp infections.

3. What is the role of carbapenems in the treatment of KPC-KP infections?

In combination treatment, meropenem may still be considered as an option for possibly enhancing bacterial killing, provided that: i) the MIC of meropenem is \leq 8mg/L and ii) a high-dose and prolonged infusion regimen is administered. With the limitations of the non-randomized design, a survival benefit by using meropenem-based regimens has indeed been argued in many observational studies, with

published data mostly referring to meropenem-including combinations for treating KPC-KP bloodstream infections (BSI). In large multicentre studies conducted in Italy and Greece an increased survival by using combinations of meropenem was observed when KPC-KP exhibited MIC ≤ 8 mg/L.^{23,24} Smaller cases series also suggested that increasing carbapenem dosage, use of prolonged infusion, and therapeutic drug monitoring (TDM) might be helpful for treating KPC-producing organisms with meropenem MICs up to 32-64 mg/L.^{26,27} However, clinical evidence supporting this possibility is preliminary,^{26,27} and the combination of two other agents showing *in vitro* activity against the given KPC-KP isolate should be considered as a reasonable alternative to carbapenem-including regimens. The administration of carbapenem-based regimens when facing meropenem MICs > 8 mg/L might be considered for MICs up to 32-64 mg/L, provided that TDM is available to monitor optimal drug exposure, in view of the risk of futility and perpetuation of resistance selection.

Since carbapenem MICs are important for including or not meropenem in combination antimicrobial regimens against KPC-KP and other CPE, the accurate measurement of carbapenem MICs of KPC-KP is a clinically relevant issue. Unfortunately, automated systems and gradient diffusion tests (which are commonly used for AST in diagnostic microbiology) may be inaccurate for measurement of carbapenem MICs with KPC-KP and other CPE.²⁸ Therefore, we recommend that carbapenem MICs of KPC-KP be determined using the reference broth microdilution methodology,²⁹ covering meropenem concentrations up to at least 32-64 mg/L.

4. What molecules can be used to treat KPC-KP infections?

A summary of the available drugs and their suggested dosage for treating KPC-KP infections is presented in table 2. Complete background information is available as Supplementary material S1.³⁰⁻⁶⁸

5. What is the role of nebulized antibiotics in the treatment of ventilator-associated pneumonia (VAP) and ventilator-associated tracheobronchitis (VAT) by KPC-KP?

Inadequate penetration of iv antibiotics that may be used against KPC-KP (including colistin, aminoglycosides, and tigecycline) to the epithelial lining fluid (ELF) have prompted the administration of aerosolized antibiotic therapy in patients with VAP.⁶⁹ Clinical outcomes were usually non-comparable between clinical studies due to heterogeneity in regimens, indications (i.e., VAP, VAT, colonization), therapeutic approaches (iv antibiotic and/or nebulized) and different nebulizing devices used.⁷⁰⁻

⁷¹ Data on KPC-producers is overall scarce.

As maximal antibiotic delivery depends on the type of aerosol generators, novel drug-device combinations stand out as a promising delivery approach in critically ill patients. A randomized trial compared fixed combination of amikacin and fosfomycin (5:2 ratio) or placebo delivered via the investigational eFlow Inline System (PARI GmbH, Germany) as adjunctive treatment to standard iv antibiotics.⁷² Distribution of multidrug-resistant (MDR) and extensively drug-resistant (XDR) isolates did not differ statistically between the two arms (10 and 5 KPC-KP were identified in target and control arms, respectively). Although clinical benefit was not

demonstrated, resistance selection was prevented and eradication of pathogens was higher in the nebulised arm.

Several studies along with a rigorous meta-analysis performed by the European Society of Clinical Microbiology and Infectious diseases (ESCMID) critically ill patients study group (ESGCIP)^{73,74} argue for an unclear clinical benefit of inhaled antibiotic in VAP due to KPC-producers.⁶⁹ A potential impact on resistance, however, needs to be further investigated.^{69,75} Recently published guidelines recommend the add-on use of inhaled colistin in patients with VAP due to carbapenem-resistant pathogens that are susceptible only to colistin.⁷⁶ The recommendation was based on a meta-analysis of four studies reporting that add-on nebulized colistin was associated with improved clinical cure. Non-responding VAP is another indication for add-on nebulized colistin.⁷⁴

6. Is prolonged infusion of beta-lactams preferable for KPC-KP?

Prolonged β -lactam infusions is intended to enhance the potency (i.e., $fT > MIC$) of these agents against pathogens with elevated MICs.⁷⁷ Since KPC-KP is intrinsically resistant to carbapenems, the use of a pharmacodynamically optimized regimen that utilizes an increased dose and infusion time has been advocated as a technique to maximize *in vivo* exposures.^{78,79} Enhancement of $fT > MIC$ can be achieved using either continuous (total daily dose infused over a 24 hr period) or prolonged infusions (conventional 0.5 hr infusion prolonged up to 6 hours^{80,81}). Carbapenem reduced stability at room temperature, requires frequent replacements of the antimicrobial at each dosing interval^{82,83} but provides pharmacodynamic

optimization and more flexibility for the nursing staff in the patient receiving polypharmacy and limited intravenous access.

7. What about source control in patients with KPC-KP infections?

The objective of source control includes the actions to control the foci of infection and to restore optimal function of the site of infection. Source control includes removal of implanted or tunnelled devices, open surgical or percutaneous drainage of infected fluids or abscesses, and surgical resection of infected tissues. Time from hypotension to implementation of source control has been found to be highly correlated with outcome. Therefore interventions to be undertaken for source control within the first 12 hours after the diagnosis of the septic syndrome, if feasible, should be considered.⁸⁴

Although source control is reported as a modifiable predictor of mortality in sepsis and septic shock⁸⁴, the data particularly from KPC-KP infections is scarce. In a two-match case control study including 99 patients in each arm comparing patients with KPC-KP and carbapenem susceptible *K. pneumoniae*, removal of focus of infection was independently associated with patient survival.⁸⁵ In a prospective observational cohort study encompassing 53 patients with BSI caused by KPC-KP, prior surgery and therapeutic interventions targeting the removal of the site of infection were strongly correlated with survival.⁸⁶ Similar conclusions were reported by Falcone et al in a retrospective analysis with 111 intensive care unit (ICU) patients with KPC-KP and septic shock in 21.6% cases. Source control process was accomplished in 95.2% of patients who survived in comparison to 31.2% who died. Cox regression analyses revealed that control of removable source of infection was

associated with favourable outcome (hazard ratio 0.14, CI 95%, $p < 0.001$).⁸⁷ In a retrospective study including 48 BSI due to KPC-KP, adjunctive source control procedures were associated with clinical response at day 7 (odds ratio 12.2, CI 95% 1.4-110, $p = 0.025$).⁸⁸

8. What is the optimal duration of treatment for KPC-KP infections?

Optimal treatment duration for KPC-KP infections is unclear. In retrospective studies a mean duration of two weeks of treatment was reported.⁸⁹ In VAP, robust data supports a reduced 8-day antibiotics course in patients receiving appropriate initial empirical therapy.⁹⁰⁻⁹² This strategy was associated with significantly more antibiotic-free days without negative impact on mortality and reduced resistance selection. Higher relapse rates in patients with non-fermenting Gram-negative bacilli were initially reported suggesting longer treatments when these pathogens were responsible for VAP.⁹⁰ An updated meta-analysis of VAP caused by non-fermenters, however, supported a reduced length of treatment (e.g., 7 days) that is currently recommended by guidelines.⁷⁶

As far as bacteremia is concerned, the evidence is even less clear. Havey et al in a large systematic review and meta-analysis encompassing 24 trials, showed that patients receiving short treatment (5-7 days) versus those receiving long treatment (7-21 days) for non-*Staphylococcus aureus* bacteremias had no significant differences in mortality, microbiological eradication and clinical cure. Randomized-controlled trials to assess the optimal duration of bacteremia in the context of MDR and KPC-producers are awaited and may provide baseline evidence that long treatments may not be necessary.⁹³ In another meta-analysis, antibiotic algorithms guided by

procalcitonin levels were found to safely guide reduced treatment duration without any negative impact on survival.⁹⁴ These findings, suggest that a holistic approach combining adequate sterilization of septic foci (microbiological eradication), optimization of antibiotic exposure in critically ill patients, and the usage of biomarkers enabling monitoring of the effectiveness of administered treatment may allow for shorter treatment durations even in the presence KPC-producers.

9. Can KPC-KP infections be prevented? And how?

The ESCMID recently released guidelines aimed to decrease the transmission of MDR Gram-negative pathogens.^{95,96} The most robust measure to prevent inter-patient transmission of KPC-KP appeared to be hand hygiene.⁹⁷ In a study showing 30% reduction of KPC-KP transmission rate, this achievement was possible in a 8 to 12 week timeframe with active surveillance, contact precautions and isolation or cohorting, but only if at least 60% compliance with hand- hygiene compliance was reached.

Additional measures include minimizing use of invasive devices, promotion of antimicrobial stewardship, a standardized approach for active surveillance of at risk populations, and protocols for discontinuation of carrier status.

Routine rectal swab surveillance of KPC-KP contacts is an important measure to enhance identification and isolation of carriers, but should not be used as a single infection-control measure to prevent KPC-KP dissemination.^{95,98-100} In this regard, multifaceted interventions are more likely to be successful. For example, the combination of daily baths with 2% chlorhexidine impregnated wipes, point-prevalence surveillance with swabs, isolation of colonized/infected patients,

cohorting of medical personnel, enhanced environmental surveillance and repetitive educational campaigns successfully controlled the further horizontal spread of a monoclonal KPC-KP strain.¹⁰¹ In another study, transmission through contaminated sinks has been suggested as the major responsible for a long-term, low-frequency hospital outbreak of KPC-KP infections, further confirming the need for accurate environmental surveillance and disinfection.¹⁰² In a study from Israel, a significant decline of the nosocomial CPE acquisition was achieved with a multiple step strategy, including ward-based mandatory guidelines for carrier isolation, patient and staff cohorting, active surveillance and new rules for microbiology identification, direct officer visits at healthcare facilities and networking.¹⁰³

An important factor to consider is the presence of super-spreaders (i.e., those carriers who more easily spread KPC-KP in their immediate environment⁹⁴). Super-spreaders are characterized by high rectal CPE concentrations and are more frequently admitted for respiratory disease.¹⁰⁴ This effect has similarities with other so called “enteropathogenetic syndromes” such as *Clostridium difficile* colitis and candidemia, at least by the means of exogenous colonization.^{104,105} In a multicentre US study, KPC-KP clearance was attributed to a reduction in the usage of urinary catheters, a factor that should be considered in the implementation of a bundle procedure.¹⁰⁶

10. Who among KPC-KP colonized patients is at increased risk of developing KPC-KP infections?

Many studies have focused on the role of KPC-KP colonization in the development of infection in order to guide the selection of appropriate interventions and administration of early appropriate treatment.

In a retrospective study involving five large Italian hospitals, bowel colonization by KPC-KP held a major role in predicting transition from colonization to infection.¹⁰⁷ The overall number of colonized sites represented the most important risk factor for KPC-KP BSI development among rectal carriers in a prospective multicentre study.^{108,109} Other risk factors for KPC-KP BSI included ICU admission, abdominal invasive procedures, chemotherapy or radiation therapy, and previous BSI.^{108,110} In a study including patients undergoing open heart surgery, colonization was the most important risk factor for KPC-KP infection.¹¹¹ In a prospective cohort study of adult patients undergoing liver transplant (LT), KPC-KP infection rates among patients non-colonized, colonized at LT, and colonized after LT were 2%, 18.2% and 46.7%, respectively.¹⁰⁸ In settings where colonization with KPC-KP is common among critically ill patients, antibiotic stewardship programs should be undertaken to optimize antimicrobial use, as shown by a study demonstrating high risk of KPC-KP VAP in colonized patients receiving prolonged antimicrobial therapy.¹¹²

Risk analysis of high mortality rates (64%) among oncohaematological patients undergoing allogenic transplant, highlighted the presence of pre-transplant KPC-KP infection and the absence of active first-line antibiotic treatment, identifying the need for targeted interventions.¹¹³ A subsequent report illustrated the safety and efficacy of allogenic HSCT in patients colonized by the KPC-KP using the “Turin

bundle”: avoidance of levofloxacin prophylaxis, treatment with gentamicin *per os* in the best window of opportunity pre-transplant, administration of tigecycline and piperacillin/tazobactam as empiric treatment of febrile neutropenia, and administration of combination regimens (e.g., colistin plus tigecycline plus meropenem) in patients with severe sepsis or septic shock.¹¹⁴ In another study, the cumulative incidence of KPC-KP BSI and septic shock at one year after haematopoietic stem cell transplantation was significantly reduced from 62.5% to 16.6% after the introduction of systematic screening with rectal swabs, contact precautions, and early targeted treatment in neutropenic patients with fever, with at least two antibiotics.¹¹⁵ Finally, a multifaceted infection control program was able to reduce both BSI due to CPE and CPE colonization, whereas monthly incidence of CPE carriage was predictive of BSI.¹¹⁶

11. Is decolonization a useful strategy in KPC-KP colonised patients?

Studies deploying oral decolonization strategies as a mean to eradicate gut carriage of KPC-KP have produced conflicting results and only one reported a survival benefit (Table 3).¹¹⁷⁻¹²³ With regard to the use of oral gentamicin for decolonization purposes, an indiscriminate use should be avoided. Indeed, this strategy has a high risk of failure and also cannot be separated from the risk of selecting gentamicin resistance (and thus of losing one of the last - if not the last - therapeutic options).^{120,123} It should therefore be reserved for very selected special conditions (e.g., very high risk of developing infection because of severe neutropenia or recurrent KPC-KP infections) on a patient-by-patients basis.¹²³

12. What is new in KPC-KP treatment options?

A handful of new compounds, expected to address the therapeutic problem of KPC-KP in the near future are summarized in Table 4 (reporting molecules in Phase 3 of clinical development).¹²⁴⁻¹³⁷

Conclusions

The optimal management of KPC-KP infections in critically ill patients relies on concerted multidisciplinary approach. On a case-by-case basis, efforts should indeed be directed towards preventing colonization, infection, or mortality. Each intervention has its peculiar issues to be addressed (preventing colonization in the patient, preventing infection in the colonized patient and colonization of his/her contacts, reducing mortality in the infected patient by rapidly diagnosing the causative agent and promptly adopting the best therapeutic strategy), but all are crucial to ultimately curtail the high mortality of KPC-KP infections. High-level evidence is urgently needed to firmly guide physicians through all these steps.

Conflict of interest

MB has received research grants from Merck, Nordic Pharma, Novartis and Pfizer, has received congress lecture fees from Astellas, Angelini ACRAF, AstraZeneca, Basilea, Biologix FZ, Gilead, Merck, Novartis, Pfizer, Tetrphase, Thermofisher, Vifor Pharma; has received consultancy fees from Achaogen, Angelini ACRAF, AstraZeneca, Basilea, Cepheid, Gilead, Menarini, Merck, Nordic Pharma, Pfizer, Rempex/The Medicine Company, Tetrphase and Vifor. GMR has received research grants from Accelerate, Alifax, Angelini ACRAF, Arrow, AstraZeneca, Basilea, Becton-Dickinson,

bioMérieux, Biotest, Cepheid, Checkpoints, Elitech, Estor, Liofilchem, Merck, Nordic
Pharma, Novartis, Pfizer, Rempex/The Medicine Company, VentorX, Zambon; has
received congress lecture fees from Accelerate, Angelini ACRAF, AstraZeneca,
Basilea, Biotest, Cepheid, Merck, Novartis, Pfizer, Thermofisher; has received
consultancy fees from Accelerate, Achaogen, Angelini ACRAF, AstraZeneca, Basilea,
Biotest, Cepheid, Curetis, Elitech, Menarini, Merck, Nordic Pharma, Pfizer,
Rempex/The Medicine Company, Thermofisher, Zambon. CV reports personal fees
from MSD Int, Gilead, Forrest Italia, Angelini and Pfizer, outside the submitted work.
GLD reports grants from Pfizer, Gilead, EU AIDA, COMBACTE-CARE (IMI ND4BB) and
honoraria from Pfizer, Achaogen, MSD, and Rempex, outside the submitted work.
EJGB has received honoraria (paid to the University of Athens) from AbbVie, Biotest,
Brahms GmbH, and The Medicines Company; has received compensation as a
consultant for Astellas Greece and for XBiotech (paid to the University of Athens);
and has received independent educational grants (paid to the University of Athens)
from AbbVie and Sanofi. He is funded by the Framework 7 program HemoSpec and
by the Horizon 2020 Marie Curie project European Sepsis Academy (granted to the
University of Athens). GD has received honoraria (paid to the University of Athens)
from Merck, Bayer, Pfizer, Astellas; has received compensation as a consultant for
Glenmark India (paid to the University of Athens). GP has received speaker's
honoraria from MSD and Pfizer.

Expert review written on behalf of Critically Ill Patients Study Group of the European
Society of Clinical Microbiology and Infectious Disease (ESCMID), Hellenic Society of
Chemotherapy (HSC) and Società Italiana di Terapia Antinfettiva (SITA).

435 The other authors declare no conflict of interests.

436

437 References

- 438 1. Rossolini GM, Arena F, Pecile P, Pollini S. Update on the antibiotic resistance
439 crisis. *Curr Opin Pharmacol* 2014; 18:56-60.
- 440 2. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, et
441 al. Clinical epidemiology of the global expansion of *Klebsiella pneumoniae*
442 carbapenemases. *Lancet Infect Dis* 2013; 13:785-96.
- 443 3. Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT, Andrasević AT,
444 et al; European Survey of Carbapenemase-Producing Enterobacteriaceae
445 (EuSCAPE) Working Group. Occurrence of carbapenemase-producing *Klebsiella*
446 *pneumoniae* and *Escherichia coli* in the European survey of carbapenemase-
447 producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study.
448 *Lancet Infect Dis* 2017; 17:153-163.
- 449 4. Maltezou HC, Kontopidou F, Dedoukou X, Katerelos P, Gourgoulis GM, Tsonou P,
450 et al. Action Plan to combat infections due to carbapenem-resistant, Gram-
451 negative pathogens in acute-care hospitals in Greece. *J Glob Antimicrob Resist*
452 2014;2:11-16.
- 453 5. Giacobbe DR, Maraolo AE, Viscoli C. Pitfalls of defining combination therapy for
454 carbapenem-resistant Enterobacteriaceae in observational studies. *Eur J Clin*
455 *Microbiol Infect Dis* 2017; doi: 10.1007/s10096-017-3010-z.
- 456 6. Banerjee R, Özenci V, Patel R. Individualized Approaches Are Needed for
457 Optimized Blood Cultures. *Clin Infect Dis* 2016; 63:1332-1339.
- 458 7. Girmenia C, Viscoli C, Piciocchi A, Cudillo L, Botti S, Errico A, et al. Management of
459 carbapenem resistant *Klebsiella pneumoniae* infections in stem cell transplant
460 recipients: an Italian multidisciplinary consensus statement. *Haematologica* 2015;
461 100:e373-6.
- 462 8. Patel R. MALDI-TOF MS for the diagnosis of infectious diseases. *Clin Chem* 2015;
463 61:100-11.
- 464 9. Bauer KA, Perez KK, Forrest GN, Goff DA. Review of rapid diagnostic tests used by
465 antimicrobial stewardship programs. *Clin Infect Dis* 2014;59 Suppl 3:S134-45.
- 466 10. Arena F, Viaggi B, Galli L, Rossolini GM. Antibiotic Susceptibility Testing: Present
467 and Future. *Pediatr Infect Dis J* 2015; 34:1128-30.
- 468 11. Kostrzewa M, Sparbier K, Maier T, Schubert S. MALDI-TOF MS: an upcoming tool
469 for rapid detection of antibiotic resistance in microorganisms. *Proteomics Clin*
470 *Appl* 2013; 7:767-78.
- 471 12. Rotova V, Papagiannitsis CC, Skalova A, Chudejova K, Hrabak J. Comparison of
472 imipenem and meropenem antibiotics for the MALDI-TOF MS detection of
473 carbapenemase activity. *J Microbiol Methods* 2017; 137:30-33.
- 474 13. Gaibani P, Galea A, Fagioni M, Ambretti S, Sambri V, Landini MP. Evaluation of
475 Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for
476 Identification of KPC-Producing *Klebsiella pneumoniae*. *J Clin Microbiol* 2016;
477 54:2609-13.

- 478 14. Hoyos-Mallecot Y, Ouzani S, Dortet L, Fortineau N, Naas T. Performance of the
479 Xpert® Carba-R v2 in the daily workflow of a hygiene unit in a country with a low
480 prevalence of carbapenemase-producing Enterobacteriaceae. *Int J Antimicrob*
481 *Agents*. 2017 Jun;49(6):774-777.
- 482 15. Salimnia H, Fairfax MR, Lephart PR, Schreckenberger P, DesJarlais SM, Johnson
483 JK, *et al*. Evaluation of the FilmArray Blood Culture Identification Panel: Results of
484 a Multicenter Controlled Trial. *J Clin Microbiol* 2016; 54:687-98.
- 485 16. Vincent JL, Brealey D, Libert N, Abidi NE, O'Dwyer M, Zacharowski K, *et al*. Rapid
486 Diagnosis of Infection in the Critically Ill, a Multicenter Study of Molecular
487 Detection in Bloodstream Infections, Pneumonia, and Sterile Site Infections. *Crit*
488 *Care Med* 2015; 43:2283-91.
- 489 17. Arena F, Giani T, Pollini S, Viaggi B, Pecile P, Rossolini GM. Molecular antibiogram
490 in diagnostic clinical microbiology: advantages and challenges. *Future Microbiol*
491 2017; 12:361-364.
- 492 18. Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E, Theuretzbacher
493 U, *et al*. Combination therapy for carbapenem-resistant Gram-negative bacteria. *J*
494 *Antimicrob Chemother* 2014; 69:2305–2309.
- 495 19. Zusman O, Altunin S, Koppel F, Dishon Benattar Y, Gedik H, Paul M. Polymyxin
496 monotherapy or in combination against carbapenem-resistant bacteria:
497 systematic review and meta-analysis. *J Antimicrob Chemother* 2017; 72:29-39.
- 498 20. Dickstein Y, Leibovici L, Yahav D, Eliakim-Raz N, Daikos GL, Skiada A, *et al*.
499 Multicentre open-label randomised controlled trial to compare colistin alone
500 with colistin plus meropenem for the treatment of severe infections caused by
501 carbapenem-resistant Gram-negative infections (AIDA): a study protocol. *BMJ*
502 *Open* 2016; 6:e009956.
- 503 21. Tzouveleakis LS, Markogiannakis A, Piperaki E, Souli M, Daikos GL. Treating
504 infections caused by carbapenemase-producing Enterobacteriaceae. *Clin Microb*
505 *Infect* 2014; 20:862-72.
- 506 22. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, *et al*.
507 Predictors of mortality in bloodstream infections caused by *Klebsiella*
508 *pneumoniae* carbapenemase-producing *K. pneumoniae*: importance of
509 combination therapy. *Clin Infect Dis* 2012; 55:943-50.
- 510 23. Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M,
511 *et al*; on behalf of ISGRI-SITA (Italian Study Group on Resistant Infections of the
512 Societa` Italiana Terapia Antinfettiva). Infections caused by KPC-producing
513 *Klebsiella pneumoniae*: differences in therapy and mortality in a multicentre
514 study. *J Antimicrob Chemother* 2015; 70:2133-43.
- 515 24. Daikos GL, Tsousi S, Tzouveleakis LS, Anyfantis I, Psychogiou M, Argyropoulou A,
516 *et al*. Carbapenemase-producing *Klebsiella pneumoniae* bloodstream infections:
517 lowering mortality by antibiotic combination schemes and the role of
518 carbapenems. *Antimicrob Agents Chemother* 2014;58: 2322-28.
- 519 25. Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Paño-Pardo
520 JR, *et al*. Effect of appropriate combination therapy on mortality of patients with
521 bloodstream infections due to carbapenemase-producing Enterobacteriaceae
522 (INCREMENT): a retrospective cohort study. *Lancet Infect Dis* 2017. pii: S1473-
523 3099(17)30228-1.
- 524 26. Del Bono V, Giacobbe DR, Marchese A, Parisini A, Fucile C, Coppo E, *et al*.
525 Meropenem for treating KPC-producing *Klebsiella pneumoniae* bloodstream

- infections: should we get to the PK/PD root of the paradox? *Virulence* 2017; 8:66-73.
27. Pea F, Della Siega P, Cojutti P, Sartor A, Crapis M, Scarparo C, et al. Might real-time pharmacokinetic/ pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing *Klebsiella pneumoniae*? *Int J Antimicrob Agents* 2017; 49:255-258.
 28. Tenover FC, Kalsi RK, Williams PP, Carey RB, Stocker S, Lonsway D, et al. Carbapenem resistance in *Klebsiella pneumoniae* not detected by automated susceptibility testing. *Emerg Infect Dis* 2006; 12:1209-13.
 29. Clinical and Laboratory Standards Institute (CLSI). 2015. Methods for dilution antimicrobial susceptibility. Tests for bacteria that grow aerobically; approved standards. Tenth edition. CLSI document M07-A10.
 30. Nation RL, Garonzik SM, Thamlikitkul V, Giamarellos-Bourboulis EJ, Forrest A, Paterson DL, et al. Dosing guidance for intravenous colistin in critically-ill patients. *Clin Infect Dis* 2017;64:565-571.
 31. Capone A, Giannella M, Fortini D, Giordano A, Meledandri M, Ballardini M, et al. SEERBIO-GRAB network. High rate of colistin resistance among patients with carbapenem-resistant *Klebsiella pneumoniae* infection accounts for an excess of mortality. *Clin Microbiol Infect* 2013; 19:E23-30.
 32. Monaco M, Giani T, Raffone M, Arena F, Garcia-Fernandez A, Pollini S, et al. Colistin resistance superimposed to endemic carbapenem-resistant *Klebsiella pneumoniae*: a rapidly evolving problem in Italy, November 2013 to April 2014. *Euro Surveill* 2014; 19.pii: 20939.
 33. Giacobbe DR, Bono VD, Trecarichi EM, De Rosa FG, Giannella M, Bassetti M, et al; ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva). Risk factors for bloodstream infections due to colistin-resistant KPC-producing *Klebsiella pneumoniae*: results from a multicenter case-control-control study. *Clin Microbiol Infect* 2015; 21:1106.e1-8.
 34. Giamarellou H. Epidemiology of infections caused by polymyxin-resistant pathogens. *Int J Antimicrob Agents*. 2016; 48:614-621.
 35. Spyropoulou A, Papadimitriou-Oliveris M, Bartzavali C, Vamvakopoulou S, Marangos M, Spiliopoulou I, et al. A ten-year surveillance study of carbapenemase-producing *Klebsiella pneumoniae* in a tertiary care Greek university hospital: predominance of KPC- over VIM- or NDM-producing isolates. *J Med Microbiol* 2016;65:240-6.
 36. Meletis G, Oustas E, Botziori C, Kakasi E, Koteli A. Containment of carbapenem resistance rates of *Klebsiella pneumoniae* and *Acinetobacter baumannii* in a Greek hospital with a concomitant increase in colistin, gentamicin and tigecycline resistance. *New Microbiol* 2015;38:417-21.
 37. Karaiskos I, Souli M, Galani I, Giamarellou H. Colistin: still a lifesaver for the 21st century? *Expert Opin Drug Metab Toxicol* 2017; 13:59-71.
 38. Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. *Expert Opin Pharmacother* 2014; 15:1351-70.
 39. Sorlí L, Luque S, Grau S, Berenguer N, Segura C, Montero MM, et al. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. *BMC Infect Dis*. 2013; 13:380.

40. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. *Clin Infect Dis* 2013; 57:524-31.
41. Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? *Clin Infect Dis* 2014; 59:88-94.
42. Gonzalez-Padilla M, Torre-Cisneros J, Rivera-Espinar F, Pontes-Moreno A, López-Cerero L, Pascual A, et al. Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant *Klebsiella pneumoniae*. *J Antimicrob Chemother* 2015; 70:905-13.
43. Machuca I, Gutiérrez-Gutiérrez B, Gracia-Ahufinger I, Rivera Espinar F, Cano Á, Guzmán-Puche J, et al. Mortality associated with bacteremia due to colistin-resistant *Klebsiella pneumoniae* with high-level meropenem resistance: importance of combination therapy without colistin and carbapenems. *Antimicrob Agents Chemother* 2017. pii: AAC.00406-17. doi: 10.1128/AAC.00406-17.
44. Stankowicz MS, Ibrahim J, Brown DL. Once-daily aminoglycoside dosing: An update on current literature. *Am J Health Syst Pharm* 2015; 72:1357-64.
45. Decker BS, Molitoris BA. Manifestations of and risk factors for aminoglycoside nephrotoxicity. *UptoDate* Nov 2016 (updated on May 21, 2015).
46. Poulakou G, Bassetti M, Righi E, Dimopoulos G. Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens. *Future Microbiol* 2014; 9:1053-69.
47. Bassetti M, Eckmann C, Bodmann KF, Dupont H, Heizmann WR, Montravers P, et al. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies. *J Antimicrob Chemother* 2013; 68 Suppl 2:5-14.
48. Montravers P, Dupont H, Bedos JP, Bret P. Tigecycline Group. Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting. *Intensive Care Med* 2014; 40:988-97.
49. Bassetti M, Poulakou G, Giamarellou H. Is there a future for Tigecycline? *Intensive Care Med* 2014; 40:1039-45.
50. Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. *Antimicrob Agents Chemother* 2013; 57:1756-62.
51. Wiskirchen DE, Koomanachai P, Nicasio AM, Nicolau DP, Kuti JL. In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against *Klebsiella pneumoniae* isolates producing a KPC carbapenemase. *Antimicrob Agents Chemother* 2011; 55:1420-7.
52. Giamarellou H, Poulakou G. Pharmacokinetic and pharmacodynamic evaluation of tigecycline. *Expert Opin Drug Metab Toxicol* 2011;7:1459-70.
53. Pontikis K, Karaikos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. *Int J Antimicrob Agents* 2014; 43:52-9.
54. Parker SL, Frantzeskaki F, Wallis SC, Diakaki C, Giamarellou H, Koulenti D, et al. Population Pharmacokinetics of Fosfomycin in Critically Ill Patients. *Antimicrob Agents Chemother* 2015; 59:6471-6.

55. Albiero J, Sy SK, Mazucheli J, Caparroz-Assef SM, Costa BB, Alves JL, et al. Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2016; 60:4128-39.
56. Lepak AJ, Zhao M, VanScoy B, Taylor DS, Ellis-Grosse E, Ambrose PG, et al. In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against *Escherichia coli*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2017; 61. pii: e00476-17. doi: 10.1128/AAC.00476-17
57. Docobo-Pérez F, Drusano GL, Johnson A, Goodwin J, Whalley S, Ramos-Martín V, et al. Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance. *Antimicrob Agents Chemother* 2015;59:5602-10.
58. Grabein B, Graninger W, Rodríguez Baño J, Dinh A, Liesenfeld DB. Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature. *Clin Microbiol Infect* 2017; 23:363-372.
59. Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, et al. Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections. *Clin Infect Dis* 2016; 63:1615-18.
60. Temkin E, Torre-Cisneros J, Beovic B, Benito N, Giannella M, Gilarranz R, et al. Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms. *Antimicrob Agents Chemother* 2017;61: pii: e01964-16.
61. Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant *Klebsiella pneumoniae* bacteremia. *Antimicrob Agents Chemother* 2017. pii: AAC.00883-17. doi: 10.1128/AAC.00883-17.
62. Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, et al. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant *Klebsiella pneumoniae* Infections. *Antimicrob Agents Chemother* 2017; 61. pii: e02097-16.
63. Perez F, El Chakhtoura NG, Papp-Wallace KM, Wilson BM5, Bonomo RA. Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy? *Expert Opin Pharmacother* 2016; 17:761-81.
64. Bulik CC, Nicolau DP. Double-carbapenem therapy for carbapenemase-producing *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2011; 55:3002-4.
65. Giamarellou H, Galani L, Baziaka F, Karaikos I. Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2013; 57: 2388-90.
66. Souli M, Karaikos I, Masgala A, Galani L, Barmpouti E, Giamarellou H. Double-Carbapenem Combination as Salvage Therapy for Untreatable Infections by KPC-2-Producing *Klebsiella pneumoniae*. *Eur J Clin Microbiol* 2017. doi: 10.1007/s10096-017-2936-5.
67. Oliva A, Scorzolini L, Castaldi D, Gizzi F, De Angelis M, Storto M, et al. Double-carbapenem regimen, alone or in combination with colistin, in the treatment of infections caused by carbapenem-resistant *Klebsiella pneumoniae* (CR-Kp). *J Infect* 2017; 74:103-6.

68. Cprek JB, Gallagher JC. Ertapenem-Containing Double-Carbapenem Therapy for Treatment of Infections Caused by Carbapenem-Resistant *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2015; 60:669-73.
69. Poulakou G, Siakallis G, Tsiodras S, Arfaras-Melainis A, Dimopoulos G. Nebulized antibiotics in mechanically ventilated patients: roadmap and challenges. *Expert Rev Anti Infect Ther* 2017; 15:211-229.
70. Lu Q, Girardi C, Zhang M, Bouhemad B, Louchahi K, Petitjean O, *et al*. Nebulized and intravenous colistin in experimental pneumonia caused by *Pseudomonas aeruginosa*. *Intensive Care Med* 2010;36:1147–55.
71. Karvouniaris M, Makris D, Zygoulis P, Triantaris A, Xitsas S, Mantzarlis K, *et al*. Nebulised colistin for ventilator-associated pneumonia prevention. *Eur Respir J* 2015; 46:1732-9.
72. Kollef MH, Ricard JD, Roux D, Francois B, Ischaki E, Rozgonyi Z, *et al*. A randomized trial of the amikacin fosfomycin inhalation system for the adjunctive therapy of Gram-negative ventilator-associated pneumonia: IASIS Trial. *Chest* 2016. pii: S0012-3692(16)62463-7.
73. Rello J, Solé-Lleonart C, Rouby JJ, Chastre J, Blot S, Poulakou G, *et al*. Use of Nebulized Antimicrobials for the Treatment of Respiratory Infections in Invasively Mechanically Ventilated Adults: A Position Paper from the European Society of Clinical Microbiology and Infectious Diseases. *Clin Microbiol Infect*. 2017. pii: S1198-743X(17)30219-7.
74. Solé-Lleonart C, Rouby JJ, Blot S, Chastre J, Blot S, Poulakou G, *et al*. Nebulization of Antiinfective Agents in Invasively Mechanically Ventilated Adults: A Systematic Review and Meta-analysis. *Anesthesiology*. 2017. pii: S1198-743X(17)30219-7.
75. Palmer LB, Smaldone GC. Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit. *Am J Respir Crit Care Med* 2014; 189:1225–33.
76. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, *et al*. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis* 2016; 1:575–82.
77. Monogue ML, Kuti JL, Nicolau DP. Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance. *Expert Review of Clinical Pharmacology* 2016; 9:459-76.
78. Berthoin K, Le Duff CS, Marchand-Brynaert J, Carryn S, Tulkens PM. Stability of meropenem and doripenem solutions for administration by continuous infusion. *J Antimicrob Chemother* 2010; 65:1073-5.
79. Pea F, Viale P, Cojutti P, Furlanut M. Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach. *Antimicrob Agents Chemother* 2012; 56:6343-8.
80. Lorente L, Lorenzo L, Martín MM, Jiménez A, Mora ML. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. *Ann Pharmacother* 2006; 40:219-23.
81. Ho VP, Jenkins SG, Afaneh G, Turbendian HK, Nicolau DP, Barie PS. Use of Meropenem by Continuous Infusion to Treat a Blakpc-2-Positive *Klebsiella pneumoniae* Blood Stream Infection. *Surgical Infections* 2011; 12:325-7.

82. Kim MK, Capitano B, Mattoes HM, Xuan D, Quintiliani R, Nightingale CH, *et al.* Pharmacokinetic and Pharmacodynamic Evaluation of Piperacillin/Tazobactam 4.5 G Q8H and 3.375 G Q6H. *Pharmacotherapy* 2002; 22:569-77.
83. Keel RA, Kuti JL, Sahm DF, Nicolau DP. Pharmacodynamic Evaluation of Commonly Prescribed Antibiotics against *Pseudomonas aeruginosa* Isolated from United States Hospitals. *American Journal Health-System Pharmacy* 2011; 68:1619-25.
84. Martínez ML, Ferrer R, Torrents E, Guillaumat-Prats R, Gomà G, Suárez D, *et al.* Edusepsis Study Group. Impact of Source Control in Patients With Severe Sepsis and Septic Shock. *Crit Care Med* 2017; 45:11-19.
85. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant *Klebsiella pneumoniae* infection and the impact of antimicrobial and adjunctive therapies. *Infect Control Hosp Epidemiol* 2008; 29:1099-106.
86. Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, *et al.* Predictors of mortality in patients with bloodstream infections caused by KPC-producing *Klebsiella pneumoniae* and impact of appropriate antimicrobial treatment. *Clin Microbiol Infect* 2011; 17:1798-803.
87. Falcone M, Russo A, Iacovelli A, Restuccia G, Ceccarelli G, Giordano A, *et al.* Predictors of outcome in ICU patients with septic shock caused by *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae*. *Clin Microbiol Infect* 2016; 22:444-50.
88. Nguyen M, Eschenauer GA, Bryan M, O'Neil K, Furuya EY, Della-Latta P, *et al.* Carbapenem-resistant *Klebsiella pneumoniae* bacteremia: factors correlated with clinical and microbiologic outcomes. *Diagn Microbiol Infect Dis* 2010; 67:180-4.
89. de Oliveira MS, de Assis DB, Freire MP, Boas do Prado GV, Machado AS, Abdala E, *et al.* Treatment of KPC-producing Enterobacteriaceae: suboptimal efficacy of polymyxins. *Clin Microb Infect* 2015; 21:179.e1–179.e7.
90. Dimopoulos G, Matthaiou DK. Duration of therapy of ventilator-associated pneumonia. *Curr Opin Infect Dis* 2016; 29:218-22.
91. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, *et al.* Pneuma Trial Group. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. *JAMA* 2003; 290:2588–2598.
92. Capellier G, Mockly H, Charpentier C, Annane D, Blasco G, Desmettre T, *et al.* Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment. *PLoS One* 2012; 7:e41290.
93. Havey TC, Fowler RA, Daneman N. Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis. *Crit Care* 2011; 15:R267.
94. Matthaiou DK, Ntani G, Kontogiorgi M, Poulakou G, Armaganidis A, Dimopoulos G. An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients. *Intensive Care Med* 2012; 38:940–9.
95. Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U, *et al.* ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. *Clin Microbiol Infect* 2014; 20 Suppl 1:1-55.

96. De Rosa FG, Corcione S, Cavallo R, Di Perri G, Bassetti M. Critical issues for *Klebsiella pneumoniae* KPC-carbapenemase producing *K. pneumoniae* infections: a critical agenda. *Future Microbiol* 2015; 10:283-94.
97. Sypsa V, Psychogiou M, Bouzala GA, Hadjihannas L, Hatzakis A, Daikos GL. Transmission dynamics of carbapenemase-producing *Klebsiella pneumoniae* and anticipated impact of infection control strategies in a surgical unit. *PLoS One* 2012; 7:e41068.
98. Gagliotti C, Ciccarese V, Sarti M, Giordani S, Barozzi A, Braglia C, et al. Active surveillance for asymptomatic carriers of carbapenemase-producing *Klebsiella pneumoniae* in a hospital setting. *J Hosp Infect* 2013; 83:330-2.
99. Lin MY, Lyles-Banks RD, Lolans K, Hines DW, Spear JB, Petrak R, et al. The importance of long-term acute care hospitals in the regional epidemiology of *Klebsiella pneumoniae* carbapenemase-producing Enterobacteriaceae. *Clin Infect Dis* 2013; 57:1246-52.
100. Giacobbe DR, Del Bono V, Marchese A, Viscoli C. Early carbapenem-resistant *Klebsiella pneumoniae* bacteraemia: should we expand the screening? *Clin Microbiol Infect.* 2014; 20:O1157-8.
101. Munoz-Price LS, De La Cuesta C, Adams S, Wyckoff M, Cleary T, McCurdy SP, et al. Successful eradication of a monoclonal strain of *Klebsiella pneumoniae* during a *K. pneumoniae* carbapenemase-producing *K. pneumoniae* outbreak in a surgical intensive care unit in Miami, Florida. *Infect Control Hosp Epidemiol* 2010; 31:1074-7.
102. Tofteland S, Naseer U, Lislevand JH, Sundsfjord A, Samuelsen O. A long-term low-frequency hospital outbreak of KPC-producing *Klebsiella pneumoniae* involving Intergenous plasmid diffusion and a persisting environmental reservoir. *PLoS One* 2013; 8:e59015.
103. Schwaber MJ, Carmeli Y. An ongoing national intervention to contain the spread of carbapenem-resistant enterobacteriaceae. *Clin Infect Dis* 2014; 58:697-703 .
104. Lerner A, Adler A, Abu-Hanna J, Cohen Percia S, Kazma Matalon M, Carmeli Y. Spread of KPC-producing carbapenem-resistant Enterobacteriaceae: the importance of super-spreaders and rectal KPC concentration. *Clin Microbiol Infect* 2015; 21:470.e1-7.
105. De Rosa FG, Corcione S, Raviolo S, Montrucchio C, Aldieri C, Pagani N, et al. Candidemia, and infections by *Clostridium difficile* and carbapenemase-producing Enterobacteriaceae: new enteropathogenetic opportunistic syndromes? *Infez Med* 2015; 23:105-16.
106. Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Ghitan M, et al. Rise and fall of KPC-producing *Klebsiella pneumoniae* in New York City. *J Antimicrob Chemother* 2016; 71:2945-8.
107. Tumbarello M, Trecarichi EM, Tumietto F, Del Bono V, De Rosa FG, Bassetti M, et al. Predictive models for identification of hospitalized patients harboring KPC-producing *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2014; 58:3514-20.
108. Giannella M, Bartoletti M, Morelli MC, Tedeschi S, Cristini F, Tumietto F, et al. Risk factors for infection with carbapenem-resistant *Klebsiella pneumoniae* after liver transplantation: the importance of pre- and posttransplant colonization. *Am J Transplant* 2015; 15:1708-15.

109. Giannella M, Trecarichi EM, De Rosa FG, Del Bono V, Bassetti M, Lewis RE, et al. Risk factors for carbapenem-resistant *Klebsiella pneumoniae* bloodstream infection among rectal carriers: a prospective observational multicentre study. Clin Microbiol Infect 2014; 20:1357-62.
110. Giacobbe DR, Del Bono V, Bruzzi P, Corcione S, Giannella M, Marchese A, et al; ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva). Previous bloodstream infections due to other pathogens as predictors of carbapenem-resistant *Klebsiella pneumoniae* bacteraemia in colonized patients: results from a retrospective multicentre study. Eur J Clin Microbiol Infect Dis 2017; 36:663-669.
111. Salsano A, Giacobbe DR, Sportelli E, Olivieri GM, Brega C, Di Biase C, et al. Risk factors for infections due to carbapenem-resistant *Klebsiella pneumoniae* after open heart surgery. Interact Cardiovasc Thorac Surg 2016; 23:762-8.
112. Sbrana F, Malacarne P, Bassetti M, Tascini C, Vegnuti L, Della Siega P, et al. Risk factors for ventilator associated pneumonia due to carbapenemase-producing *Klebsiella pneumoniae* in mechanically ventilated patients with tracheal and rectal colonization. Minerva Anestesiol 2016; 82:635-40.
113. Girmenia C, Rossolini GM, Picocchi A, Bertaina A, Pisapia G, Pastore D, et al; Gruppo Italiano Trapianto Midollo Osseo (GITMO). Infections by carbapenem-resistant *Klebsiella pneumoniae* in SCT recipients: a nationwide retrospective survey from Italy. Bone Marrow Transplant 2015; 50:282-8.
114. De Rosa FG, Corcione S, Raviolo S, Bruno B, Busca A. Management of Carbapenem-Resistant *K. pneumoniae* in Allogenic Stem Cell Transplant Recipients: The Turin Bundle. New Microbiologica 2017. In press.
115. Forcina A, Baldan R, Marasco V, Cichero P, Bondanza A, Noviello M, et al. Control of infectious mortality due to carbapenemase-producing *Klebsiella pneumoniae* in hematopoietic stem cell transplantation. Bone Marrow Transplant 2017; 52:114-9.
116. Viale P, Tumietto F, Giannella M, Bartoletti M, Tedeschi S, Ambretti S, et al. Impact of a hospital-wide multifaceted programme for reducing carbapenem-resistant Enterobacteriaceae infections in a large teaching hospital in northern Italy. Clin Microbiol Infect. 2015; 21:242-7.
117. Zuckerman T, Benyamini N, Sprecher H, Fineman R, Finkelstein R, Rowe JM, et al. SCT in patients with carbapenem resistant *Klebsiella pneumoniae*: a single center experience with oral gentamicin for the eradication of carrier state. Bone Marrow Transplant 2011; 46: 1226–30.
118. Saidel-Odes L, Polachek H, Peled N, Riesenberk K, Schlaeffer F, Trabelsi Y, et al. A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem resistant *Klebsiella pneumoniae* carriage. Infect Control Hosp Epidemiol. 2012; 33: 14–9.
119. Lübbert C, Fauchaux S, Becker-Rux D, Laudi S, Dürrbeck A, Busch T, et al. Rapid emergence of secondary resistance to gentamicin and colistin following selective digestive decontamination in patients with KPC-2-producing *Klebsiella pneumoniae*: a single-centre experience. Int J Antimicrob Agents. 2013;42:565-70.
120. Tascini C, Sbrana F, Flammini S, Tagliaferri E, Arena F, Leonildi A, et al. Oral gentamicin gut decontamination for prevention of KPC-producing *Klebsiella*

- 858 *pneumoniae* infections: relevance of concomitant systemic antibiotic therapy.
 859 Antimicrob Agents Chemother. 2014; 58: 1972–6.
- 860 121. Oren I, Sprecher H, Finkelstein R, Hadad S, Neuberger A, Hussein K, et al.
 861 Eradication of carbapenem resistant Enterobacteriaceae gastrointestinal
 862 colonization with nonabsorbable oral antibiotic treatment: a prospective
 863 controlled trial. Am J Infect Control. 2013; 41: 1167–72.
- 864 122. Tascini C, Urbani L, Sbrana F, Forfori F, Licitra G, Leoni C, et al. Oral
 865 administration of gentamicin for prophylaxis of KPC-producing *Klebsiella*
 866 *pneumoniae* gut colonization in patients treated with a novel parenchymal-
 867 sparing liver surgery: the GEN Gut study. Intensive Care Med. 2016;42:124-5.
- 868 123. Machuca I, Gutiérrez-Gutiérrez B, Pérez Cortés S, Gracia-Ahufinger I, Serrano
 869 J, Madrigal MD, et al. Oral decontamination with aminoglycosides is associated
 870 with lower risk of mortality and infections in high-risk patients colonized with
 871 colistin-resistant, KPC-producing *Klebsiella pneumoniae*. J Antimicrob Chemother.
 872 2016;71:3242-9.
- 873 124. Bassetti M, Righi E. New antibiotics and antimicrobial combination therapy
 874 for the treatment of gram-negative bacterial infections. Curr Opin Crit Care 2015;
 875 21:402-11
- 876 125. <https://clinicaltrials.gov/ct2/results?term=ceftazidime+avibactam&Search=Search>
 877 earch
 878 a. assessed 28.02.2017
- 879 126. <https://clinicaltrials.gov/ct2/results?term=ceftaroline+avibactam&Search=Search>
 880 earch
 881 a. assessed 28.02.2017
- 882 127. <https://clinicaltrials.gov/ct2/results?term=imipenem+relebactam&Search=Search>
 883 earch
- 884 128. <https://clinicaltrials.gov/ct2/results?term=carbavance&Search=Search>
- 885 129. Cloutier DJ, Miller LG, Komirenko AS, Cebrik DS, Krause KM, Keepers TR, et
 886 al. Plazomicin versus Meropenem for the Treatment of Complicated Urinary Tract
 887 infection (cUTI) and Acute Pyelonephritis (AP): Results of the EPIC Study.
 888 Presented at: 27th European Congress of Clinical Microbiology and Infectious
 889 Diseases (ECCMID), Vienna, Austria, April 22-25, 2017.
- 890 130. Connolly LE, Jubb AM, O'Keeffe B, Serio AW, Smith A, Gall J, et al. Plazomicin
 891 Is Associated With Improved Survival and Safety Compared With Colistin in the
 892 Treatment of Serious Infections Due to Carbapenem-resistant
 893 Enterobacteriaceae: Results of the CARE Study. Presented at: 27th European
 894 Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna,
 895 Austria, April 22-25, 2017.
- 896 131. Falagas ME, Skolidis T, Vardakas KZ, Legakis NJ. Hellenic Cefiderocol Study
 897 Group. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-
 898 negative bacteria collected from inpatients in Greek hospitals. J Antimicrob
 899 Chemother 2017; 72:1704-1708.
- 900 132. <https://clinicaltrials.gov/ct2/results?term=eravacycline&Search=Search>
- 901 133. Sutcliffe JA, O'Brien W, Fyfe C, Grossman TH. Antibacterial activity of
 902 eravacycline (TP-434), a novel fluorocycline, against hospital and community
 903 pathogens. Antimicrob Agents Chemother 2013; 57:5548-5558.
- 904 134. Connors KP, Housman ST, Pope JS, Russomanno J, Salerno E, Shore E, et al.
 905 Phase I, open-label, safety and pharmacokinetic study to assess

bronchopulmonary disposition of intravenous eravacycline in healthy men and women. *Antimicrob Agents Chemother* 2014; 58:2113-2118.

135. Zhang Y, Lin X, Bush K. In vitro susceptibility of β -lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline. *J Antibiot (Tokyo)* 2016; 69:600-4.

136. Solomkin J, Evans D, Slepavicius A, Lee P, Marsh A, Tsai L, et al. Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial. *JAMA Surg* 2017; 152:224-232.

137. TETRAPHASE ANNOUNCES TOP-LINE RESULTS FROM IGNITE2 PHASE 3 CLINICAL TRIAL OF ERAVACYCLINE IN CUTI. TETRAPHASE PHARMACEUTICALS, 2015. Available at: <http://ir.tphase.com/releasedetail.cfm?releaseid=930613>

954
955

956 **Table 1. Clinical question defined by the panel and related answers based on**
957 **expert opinion**

Question 1	<p>How can the laboratory speed-up KPC-KP identification and susceptibility testing?</p> <p><i>Diagnostic technologies could speed-up the diagnosis of KPC-KP infections and potentially improve patients' outcome. However, whether or not they should be introduced into the laboratory workflow remain a choice to be carefully balanced locally, according to the available resources and personnel in every single hospital.</i></p>
Question 2	<p>What is currently the best treatment for KPC-KP infections?</p> <p><i>Combination treatment should be preferred to treat KPC-KP infections compared to monotherapy in the case of severe infections and for critically ill patients. For non-critically-ill patients without severe infections, results from randomized clinical trials are needed for ultimately weighing the related benefits and costs, also in terms of induction of resistance.</i></p>
Question 3	<p>What is the role of carbapenems in the treatment of KPC-KP infections?</p> <p><i>Administration of high-dose (e.g., 2 grams q 8 hours), prolonged infusion meropenem could be beneficial in KPC-KP infections if MIC is ≤ 8 mg/L. For MIC up to 32-64 mg/L, meropenem administration should be considered if TDM is available to monitor optimal drug exposure.</i></p>
Question 4	<p>What molecules can be used in the treatment of KPC-KP infections?</p> <p><i>Various molecules can be used in combination treatment against KPC-KP, including aminoglycosides, polymyxins, tigecycline, fosfomycin, and carbapenems in selected cases (see table 2 for details).</i></p>
Question 5	<p>What is the role of nebulized antibiotics in the treatment of ventilator-associated pneumonia (VAP) and ventilator-associated tracheobronchitis (VAT) by KPC-KP?</p> <p><i>The use of nebulised antibiotics could be useful in selected clinical scenario, especially when there is lung involvement (e.g., use of inhaled colistin in VAP due to carbapenem-resistant pathogens).</i></p>
Question 6	<p>Is prolonged infusion of beta-lactams preferable for KPC-KP?</p> <p><i>To achieve pharmacodynamic optimization in KPC-directed regimens,</i></p>

prolonged infusion should be combined with high-dose regimens. To achieve pharmacodynamic optimization in KPC-directed regimens, prolonged infusion should be combined with high-dose regimens.

Question 7 What about source control in patients with KPC-KP infections?

Although data among patients with KPC-KP infections is limited, source control in this population has been associated with favourable outcomes and should be performed promptly whenever possible.

Question 8 What is the optimal duration of treatment for KPC-KP infections?

Treatment duration for KPC-KP infections should vary according to the source of the infection. Factors such as achievement of microbiological eradication, use of biomarkers and optimization of antibiotic exposure could be used to reduce treatment duration

Question 9 Can KPC-KP infections be prevented? And how?

Multifaceted infection control components are needed to decrease the rates of colonization and cross transmission of KPC-Kp.

Question 10 Who among KPC-KP colonized patients is at increased risk of developing KPC-KP infections?

Proper management of colonized patients, including surveillance and antimicrobial stewardship programs, are essential and contribute to ensure an early and appropriate treatment in patients with signs of infection.

Question 11 Is decolonization a useful strategy in KPC-KP colonised patients?

Decolonization of KPC-Kp carriers is currently not supported by large studies and may be considered only in selected cases.

Question 12 What's new in KPC-KP treatment options?

Novel compounds targeting KPC-KP are under investigation and appear promising for their treatment, including meropenem-vaborbactam, imipenem-relebactam, plazomicin, cefiderocol, and eravacycline. Among these, meropenem/vaborbactam and plazomicin have already demonstrated some interesting and favourable results in treating KPC-KP infections.

961 **Table 2. Antimicrobial agents Against *Klebsiella pneumoniae* carbapenemase-producing *Klebsiella pneumoniae* (KPC-KP).**

Drug	Loading dose	Daily dose for normal renal function	Comments
Polymyxins [ref. 30-41]			
Colistin ^a	9 million IU	4.5 million IU IV q 12h. Intrathecal/intraventricular: 125.000-250.000 IU Inhaled: 1 to 3 million IU q 8h	For infections caused by organisms with MIC >0.5 mg/L, it is advisable to use colistin as part of combination therapy. For dosage adjustment in patients with renal failure refer to nation R <i>et al.</i> ²⁹
Polymyxin B ^b	Not required	7500–12500 IU/Kg q 12 h q 12 h Intrathecal/intraventricular: 50000 IU q 24 h	No dose adjustment for renal failure.
Aminoglycosides [ref. 42-45]			
Gentamicin	Not required when administered in pulse dosing schemes	5 to 7 mg/kg infused over 1 h	Aminoglycosides can be useful as part of combination regimens for treating KPC-KP infections, especially if colistin resistance is documented. Pulse dosing is preferable to multiple daily doses; desired peak serum levels are about 10 times the MIC of the organism. Adjust doses according to Hartford nomogram. ⁴³
Amikacin	Not required when administered in	15 to 20 mg/kg infused over 1 h	

pulse dosing
schemes

Tigecycline [ref. 21,22,46-52]	100-200 mg	50-100 mg q 12 h IV	For BSIs or pneumonia or when tigecycline MIC > 0.5 mg/L, higher doses are recommended (loading dose, 200 mg followed by 100 mg q 12 h), preferably in combination with another agent. Not to be used in urinary tract infections, no concentrations in urine.
Fosfomycin [ref. 38,53-58]	Not required	18 to 24 g IV in 3 to 4 doses	Fosfomycin could be used in combination treatment for KPC-KP infections administered as 6 to 8g every 8 hours. Resistance can occur during treatment and should be monitored. The potential of fosfomycin to select resistant mutants precludes its use as a single agent.
Ceftazidime/ avibactam [ref. 59-63]	Not required	2.5g q 8 h IV infused over 2 h	Approved for complicated urinary tract and intra-abdominal infections; active <i>in vitro</i> against <i>Enterobacteriaceae</i> producing ESBLs, AmpC, KPC and OXA-48. Clinical experience for carbapenem-resistant <i>Enterobacteriaceae</i> is currently limited to case series. ⁵⁶⁻⁵⁹ Despite concerns of resistance selection raised by a few reports that might support the use of ceftazidime/avibactam in combination with other agents for treating KPC-KP infections, whether it should be ultimately used alone or combined remain unclear, and requires further dedicated investigation.
Meropenem [ref. 23-29,64-68]	1-2 g	2 g q 8 h IV infused over 3-6 h	Meropenem should be used in combination with another active agent; the probability of response is higher when meropenem MIC ≤ 8 mg/L. Salvage therapy with association of two carbapenems, e.g. ertapenem plus either meropenem or doripenem can be considered when other options are not suitable or available.

962 a. 1 mg of colistin base activity is contained in 2.4 mg colistimethate which is equivalent to 30,000 IU.

963 b. 1 mg of polymyxin B is equivalent to 10,000 IU

964

965

966 **Table 3. Summary of studies reporting decolonisation strategies as a means of eradicating KPC-KP carriage**

Study	Design-Population	Intervention	Main outcome	Comment
Zuckerman T et al, 2011 [ref. 117]	Pilot study in haemato-oncology and Bone Marrow Transplant unit (15 patients) Goal: To eradicate carbapenem resistant <i>Klebsiella pneumoniae</i> (CRKP) from rectal carriage	Oral gentamicin at a dose of 80 mg q.i.d. was administered to all identified carriers until eradication [median duration of 27 days (range: 7–90)].	Eradication rate achieved was 66% (10/15) and lasted for a median of 9 months (range: 2–10); discontinuation of persistent bacteremia occurred in 62.5% (5/8) and nosocomial spread of CRKP carrier state ceased	No gentamicin resistance was detected in blood isolates during oral gentamicin treatment. Administration of intensive chemotherapy and SCT was feasible.
Saidel-Odes L, et al, 2012 [ref. 118]	A randomized, double-blind, placebo-controlled trial in a 1,000-bed tertiary-care university hospital.	Forty adults with CRKP-positive rectal swab cultures. The SDD arm received oral gentamicin and polymyxin E gel (0.5 g 4 times per day) and oral solutions of gentamicin (80 mg 4 times per day) and polymyxin E (1×10^6 units 4 times per day for 7 days).	Positive for CRKP rectal cultures were significantly reduced by 2 weeks [16.1% in the placebo arm and 61.1% in the SDD arm were negative (odds ratio, 0.13; 95% confidence interval, 0.02–0.74; $P < 0.0016$)]. Difference between the 2 arms was still maintained at 6 weeks (33.3% vs 58.5%). There was no evidence of an increase in either gentamicin or polymyxin E MIC, among CRKP isolates.	SDD was effective as decolonization strategy for selected patients colonized with CRKP, such as transplant recipients or immunocompromised patients pending chemotherapy and candidates for major intestinal or oropharyngeal surgery.

Lübbert C et al, 2015 [ref. 119]	A single centre outbreak of KPC-2, affecting 90 patients hospitalized over 28 months. Retrospective analysis, of patients who received selective digestive decontamination (SDD) compared with the remaining patients harbouring KPC-2-KP.	14 consecutive patients were treated with a short course (7days) of SDD regimen consisting of colistin (1 million units q.i.d.) and gentamicin (80 mg q.i.d.) as oral solutions, and colistin /gentamicin gel (0.5g) to the oral cavity.	Decolonisation of KPC-2-KP was achieved in 6/14 patients (43%) after a mean of 21days (range12–40 days), but was also observed in 23/76 (30%). Secondary resistance to colistin(by 19%) and gentamicin (by 45%) was observed in SDD group but not in the comparative group. of thenon-SDD controls (P = 0.102).	The SDD approach was not sufficiently effective for decolonization and was associated with high rates of resistance in subsequent cultures.
Tascini C, et al, 2014 [ref. 120]	A pilot non-blinded, prospective study in three Italian hospitals to assess the feasibility of administering oral gentamicin for KPC-Kp gut decontamination. Patients enrolled had gut colonization by gentamicin-susceptible KPC-Kp and were candidates for planned surgery, major medical intervention, or need for patient transfer.	Oral gentamicin, 80 mg four times daily, was administered to 50 consecutive patients over an 8 month period. A separate analysis was performed with the 23 patients receiving oral gentamicin alone and with the 27 patients who received Concomitant Systemic Antibiotic Treatment (CSAT). Oral gentamicin was given for a median of 16 days (interquartile range, 10 to 27 days).	KPC-Kp infections were documented in 5/34 (15%) successfully decontaminated patients compared to 12/16 (73%) persistent carriers (P<0.001). The decontamination rate was 96% (22/23) in patients receiving oral gentamicin only, compared to 44% (12/27) of those treated with oral gentamicin and CSAT (P<0.001). Gentamicin-resistant KPC-Kp strains were isolated from stools of 4/16 persistent carriers	useful for gut decontamination and prevention of infection due to KPC-Kp, especially in patients not receiving CSAT. No difference in overall mortality was observed between decontaminated and persistently colonized patients.
Oren I, et al, 2013 [ref. 121]	A semi-randomized, prospective, controlled trial was conducted to eradicate	152 patients were included; 50 patients received 1 of the 3 drug regimens: gentamicin, 26; colistin, 16; both drugs,	Eradication rates in the 3 treatment groups were 42%, 50%, and 37.5%, respectively, each significantly higher than the 7%	Administration of oral nonabsorbable antibiotics was an effective and safe strategy for eradication of CRE colonization and, thereby, may reduce patient-to-

	CRE colonization using oral nonabsorbable antibiotics.	8, followed for a median duration of 33 days and 102 were followed for spontaneous eradication for a median duration of 140 days (controls). Antibiotic selection was based on isolate's in vitro susceptibility.	spontaneous eradication rate in the control group ($P < .001$, $P < .001$, and $P = .004$, respectively) with no difference between the regimens. No significant adverse effects were observed.	patient transmission and incidence of clinical infection. A trend towards lower mortality among patients who succeeded eradication on treatment (2/22, 9%), compared with those who failed eradication on treatment (9/28, 32%) was observed ($p=0.052$)
Tascini C et al, 2015 [ref. 122]	A 1:1 case control study exploring prevention of KPC-Kp gut colonization in patients that undergo hepatectomy with oral gentamicin in an endemic setting	All 31 consecutive patients who underwent liver resections in the last year treated orally with gentamicin; controls were 31 patients who underwent surgery in the same ward in the previous year without gentamicin prophylaxis.	The overall gut colonization rate in the intervention group was 3 % (1/31) versus 29 % (9/31) in the control group ($p = 0.016$). The only KPC-Kp strain isolated in the gentamicin-treated group retained susceptibility to gentamicin	Oral administration of gentamicin might be effective to avoid KPC-Kp gut colonization without adverse events.
Machuca I et al, 2016 [ref.123]	A retrospective cohort study of patients colonized by KPCKP in two hospitals during an outbreak with colistin-resistant KPCKP strain, exploring whether decolonization therapy (DT) with aminoglycosides had a protective effect in selected	77 patients at high risk [(a) neutropenia (b) major surgery; (c) multiple comorbidities], with rectal colonization by colistin-resistant KPCKP were followed for 180 days. Oral aminoglycosides (gentamicin or combination of neomycin/streptomycin) were administered in 44 patients.	At 180 days of follow-up, decolonization was associated with a lower risk of mortality in multivariate analyses (HR 0.18; 95% CI 0.06–0.55) and a lower risk of KPCKP infections (HR 0.14; 95% CI 0.02–0.83) and increased microbiological success (HR 4.06; 95%CI 1.06–15.6). Beneficial effects were more favorable with gentamicin.	Intestinal decolonization with aminoglycosides is associated with a reduction in crude mortality and KPCKP infections.

patients.

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983 **Table 4. New antimicrobials with potential activity against KPC producing Enterobacteriaceae**

Antibiotic	Antibiotic class	Resistant phenotypes	Status of development	Company	Comments
Ceftazidime/ avibactam	β -lactam/ β -lactam inhibitor	Activity against Enterobacteriaceae producing KPCs, ESBLs, OXA, AmpC enzymes. No activity against Class B beta-lactamases (MBL, VIM, NDM). Avibactam offers no enhanced activity against <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter</i> <i>baumannii</i>	-Non-inferiority versus imipenem and meropenem in Phase 2 clinical trials for the treatment of cUTIs and cIAls respectively -Licensed in US, and EU for cUTIs and cIAls -Awaiting results of Phase 3 trial in VAP Phase 1 study on PKs of critically ill patients planned	US: Allergan Inc. EU: Astra Zeneca	Ceftazidime-avibactam was recently licensed for the treatment of cUTIs and cIAls in US and Europe. ^{124,125} The registration trials, however, did not include CRE isolates.
Ceftaroline/ avibactam	β -lactam/ β -lactam inhibitor	ESBL- and KPC-producing Enterobacteriaceae. Avibactam effectively inhibits Ambler class A (e.g., ESBL and KPC), C (AmpC), and some D (OXA- like) enzymes. No activity against <i>A.</i> <i>baumannii</i> or <i>P.</i> <i>aeruginosa</i> No activity against Class B enzymes (MBL)	-Completed phase 1 trials and one phase 2 trial in cUTIs -Completed a Phase 2 trial in cUTIs versus doripenem, and three Phase 1 trials awaiting results	Forest Laboratories	Ceftaroline-avibactam has a promising in vitro spectrum; results from clinical trials are pending. ^{124,126}
Imipenem/	carbapenem/ β -	Class A and C β -	Completed phase 2 trial in	Merck	Relebactam is under investigation in

relebactam	lactamase inhibitor (diazabicyclooctane)	lactamases, porin mutations, Class D (OXA-48 not consistently) No activity against MBL	cUTI, currently in Phase 3 trials versus colistin against imipenem resistant pathogens and versus piperacillin tazobactam in bacterial pneumonia		combination with imipenem/cilastatin with Phase 3 trials underway versus colistin for imipenem-resistant pathogens and versus piperacillin/tazobactam in bacterial pneumonia. ^{124,63,127}
Meropenem/vaborbactam (RPX 7009)	carbapenem/boronic acid-based β -lactamase inhibitor	Class A β -lactamases (KPC and most AmpC) No activity against MBL and Class D OXA-48	-Completed Phase 3 trial in cUTI, -Ongoing Phase 3 trial in various infections caused by carbapenem resistant bacteria, -Planned Phase 3 trial in VAP	The Medicines company	The boronic-based beta-lactamase inhibitor vaborbactam combined with meropenem (Carbavance) is currently in Phase 3 trials. ^{63,128}
Plazomicin	New aminoglycoside (neoglycoside)	Various Gram-positive and Gram-negative organisms Not active against bacteria harboring ribosomal methyltransferases (mostly NDM-1 strains)	Completed two phase 3 trials (cUTIs and serious infections by CRE) Submission for FDA approval in 2017 and EMA in 2018	Achaogen	A new parenteral hemisynthetic aminoglycoside with favourable pharmacokinetics and safety profile, plazomicin, holds also promise against KPC-producers. ^{63,124} Its efficacy against carbapenem-producing bacteria has been recently demonstrated in serious infections including BSI, HAP/VAP, and cUTI. ^{129,130}
Cefiderocol, S-649266	Siderophore cephalosporin	ESBL, Class A (KPC) and Class B (NDM-1) carbapenemases and OXA-type enzymes, broad range of pathogens including A.	Completed phase 2 trial in UTI, currently in Phase 3 trials for severe infections by CRE. Phase 3 in nosocomial	Shionogi	Cefiderocol (formerly S-649266) is a promising siderophore cephalosporin, showing high activity against carbapenem-resistant Gram-negative bacteria, and it is currently in Phase 3 trial. ^{63,124,131}

baumannii, *P. aeruginosa*,
S. maltophilia, and
 Enterobacteriaceae (CRE)

pneumonia scheduled

Eravacycline	Tetracycline	ESBL, KPC, NDM and OXA producing <i>Escherichia coli</i> and <i>K. pneumoniae</i> . Active against <i>A. baumannii</i> and <i>S. maltophilia</i> . Not active against <i>P. aeruginosa</i>	Completed phase 2 trials in cIAI, Currently in Phase 3 trials in cIAI (versus meropenem) and in cUTI (versus ertapenem/levofloxacin)	Tetraphase Pharmaceuticals Inc	Eravacycline is a novel fluorocycline with in vitro activity against Enterobacteriaceae harbouring a variety of resistance genes (ESBLs or carbapenemases), potential activity against <i>A. baumannii</i> , but not against <i>P. aeruginosa</i> . ^{63,124,,132,133} Compared to tigecycline, it is more potent <i>in vitro</i> two- to eightfold against Gram-negative bacilli and exhibits 1-fold higher C_{max} and AUC_{0-12} in ELF. ^{134,135} Non-inferiority was demonstrated in a Phase 3 study evaluating the safety and efficacy of eravacycline versus ertapenem in cIAI, ¹³⁶ but not in the trial of cUTIs compared to levofloxacin. ¹³⁷
--------------	--------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------	--------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------